Modulation of vessel modification might account for a relevant part of tumor regression in these studies, however it is not entirely clear whether VEGFR-inhibition also directly affects DC phenotype and function and might even counterbalance some of the induced positive anti-cancer effects. The gene discussed is KDR; the disease is cancer.